Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 21 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-2.64 Insider Own6.34% Shs Outstand54.58M Perf Week-8.90%
Market Cap73.06M Forward P/E- EPS next Y-1.04 Insider Trans-0.62% Shs Float51.45M Perf Month0.00%
Income-145.34M PEG- EPS next Q-0.59 Inst Own99.33% Short Float9.98% Perf Quarter-85.24%
Sales28.29M P/S2.58 EPS this Y25.30% Inst Trans1.35% Short Ratio2.32 Perf Half Y-85.91%
Book/sh-0.30 P/B- EPS next Y47.12% ROA-79.82% Short Interest5.14M Perf Year-87.17%
Cash/sh2.06 P/C0.65 EPS next 5Y20.00% ROE-423.43% 52W Range1.11 - 11.26 Perf YTD-87.76%
Dividend Est.- P/FCF- EPS past 5Y6.04% ROI-189.10% 52W High-88.19% Beta1.13
Dividend TTM- Quick Ratio2.93 Sales past 5Y176.17% Gross Margin89.03% 52W Low19.82% ATR (14)0.14
Dividend Ex-Date- Current Ratio3.07 EPS Y/Y TTM-362.82% Oper. Margin-474.91% RSI (14)30.01 Volatility8.37% 8.67%
Employees165 Debt/Eq- Sales Y/Y TTM30.53% Profit Margin-513.80% Recom1.55 Target Price6.67
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q-1.39% Payout- Rel Volume0.40 Prev Close1.35
Sales Surprise-15.04% EPS Surprise-2.61% Sales Q/Q-26.02% EarningsMay 08 BMO Avg Volume2.21M Price1.33
SMA20-8.53% SMA50-26.34% SMA200-80.28% Trades Volume889,005 Change-1.48%
Date Action Analyst Rating Change Price Target Change
Apr-16-24Downgrade Robert W. Baird Outperform → Neutral $20 → $2
Apr-15-24Downgrade RBC Capital Mkts Outperform → Sector Perform $24 → $3
Aug-11-23Downgrade Oppenheimer Outperform → Perform $14 → $9
Jan-20-23Initiated RBC Capital Mkts Outperform $23
Sep-30-20Initiated Truist Buy $35
Jul-01-20Reiterated H.C. Wainwright Buy $6 → $9
Jul-01-20Initiated Cowen Outperform
Apr-09-20Initiated Craig Hallum Buy $4.50
Dec-20-19Initiated Oppenheimer Outperform
Mar-05-19Resumed Jefferies Buy $3.50 → $10
Jun-18-24 04:52AM
Jun-17-24 07:00AM
May-17-24 10:44AM
09:35AM Loading…
May-16-24 09:35AM
May-08-24 01:22PM
May-07-24 10:18AM
May-02-24 08:00AM
May-01-24 08:00AM
Apr-16-24 11:46AM
12:54PM Loading…
Apr-15-24 12:54PM
Apr-05-24 04:00PM
Mar-27-24 08:41AM
Mar-25-24 10:00AM
Mar-20-24 10:32AM
Mar-07-24 01:41PM
Mar-06-24 07:14AM
Mar-05-24 05:10PM
Feb-21-24 07:00AM
Feb-20-24 07:00AM
04:00PM Loading…
Feb-16-24 04:00PM
Jan-30-24 08:13PM
Jan-22-24 09:56AM
Jan-17-24 09:55AM
Jan-04-24 04:30PM
Dec-29-23 06:45AM
Dec-07-23 04:30PM
Nov-20-23 04:01PM
Nov-14-23 04:05PM
Nov-09-23 04:30PM
Nov-08-23 04:32PM
Nov-07-23 07:55AM
Oct-24-23 07:01AM
Oct-11-23 09:55AM
Oct-06-23 04:00PM
Sep-21-23 04:00PM
Sep-20-23 09:02AM
Sep-19-23 04:51PM
Sep-12-23 04:00PM
Sep-06-23 04:01PM
Aug-17-23 04:01PM
Aug-11-23 04:01PM
Aug-10-23 08:40AM
Jul-31-23 12:03PM
Jul-27-23 07:01AM
Jul-25-23 03:48PM
Jul-13-23 04:30PM
Jul-03-23 04:23AM
Jun-21-23 04:01PM
Jun-12-23 07:59AM
Jun-02-23 04:30PM
May-26-23 08:10AM
May-17-23 04:01PM
May-16-23 11:50AM
May-11-23 08:35AM
May-09-23 04:01PM
May-04-23 10:00AM
May-03-23 07:01AM
Apr-27-23 07:01AM
Apr-18-23 11:03AM
Apr-06-23 04:00PM
Mar-22-23 09:01AM
Mar-08-23 12:12PM
Mar-07-23 05:15PM
Mar-06-23 04:01PM
Feb-15-23 01:00PM
Feb-13-23 07:15AM
Feb-10-23 04:01PM
Feb-07-23 07:15AM
Jan-30-23 04:01PM
Jan-20-23 02:17PM
Jan-09-23 04:17PM
Jan-05-23 04:01PM
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Braunstein ScottCHAIRMAN AND CEOMar 27 '24Option Exercise4.2850,000214,000273,512Mar 27 11:55 AM
Shafer ChristinaCHIEF COMMERCIAL OFFICERFeb 20 '24Sale9.562,15320,58360,308Feb 22 04:05 PM
MANNING MARTHA ESVP, GEN. COUNSEL & CORP. SEC.Feb 20 '24Sale9.571,89418,12652,966Feb 22 04:05 PM
Braunstein ScottCHAIRMAN AND CEOFeb 16 '24Sale9.9411,850117,789223,512Feb 21 04:05 PM
Pfanstiel StevenCFO AND COOFeb 16 '24Sale9.973,09230,82771,697Feb 21 04:05 PM
Hulihan JosephCHIEF MEDICAL OFFICERFeb 16 '24Sale9.982,81428,08466,635Feb 21 04:06 PM
Braunstein ScottCHAIRMAN AND CEOAug 08 '23Sale8.9430268160,762Aug 08 09:05 PM
Pfanstiel StevenCFO AND COOAug 08 '23Sale8.931412549,324Aug 08 09:05 PM
Hulihan JosephCHIEF MEDICAL OFFICERAug 08 '23Sale8.931311647,614Aug 08 09:05 PM
Shafer ChristinaCHIEF COMMERCIAL OFFICERAug 08 '23Sale8.93119840,626Aug 08 09:05 PM
MANNING MARTHA ESVP, GEN. COUNSEL & CORP. SEC.Aug 08 '23Sale8.93119833,025Aug 08 09:05 PM
Braunstein ScottCHAIRMAN AND CEOAug 07 '23Sale9.556,41361,244160,792Aug 08 09:05 PM
Hulihan JosephCHIEF MEDICAL OFFICERAug 07 '23Sale9.552,88927,59047,627Aug 08 09:05 PM
Pfanstiel StevenCFO AND COOAug 07 '23Sale9.542,79026,61749,338Aug 08 09:05 PM
Shafer ChristinaCHIEF COMMERCIAL OFFICERAug 07 '23Sale9.522,38522,70540,637Aug 08 09:05 PM
MANNING MARTHA ESVP, GEN. COUNSEL & CORP. SEC.Aug 07 '23Sale9.542,16920,69233,036Aug 08 09:05 PM